147 related articles for article (PubMed ID: 30691310)
1. Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV.
Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):370-377. PubMed ID: 30691310
[TBL] [Abstract][Full Text] [Related]
2. Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate.
Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
Rep Biochem Mol Biol; 2019 Jan; 7(2):156-166. PubMed ID: 30805395
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
[TBL] [Abstract][Full Text] [Related]
4. Chitosan nanoparticles containing fusion protein (Hspx-PPE44-EsxV) and resiquimod adjuvant (HPERC) as a novel booster vaccine for
Hoseinpur R; Hasani A; Baradaran B; Abdolalizadeh J; Amini Y; Salehi R; Samadi Kafil H; Azizian K; Memar MY; Gholizadeh P; Hasani A
J Biomater Appl; 2022 Jul; 37(1):40-47. PubMed ID: 35430919
[TBL] [Abstract][Full Text] [Related]
5. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
[TBL] [Abstract][Full Text] [Related]
6. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
7. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
[TBL] [Abstract][Full Text] [Related]
8. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying.
Christensen D; Foged C; Rosenkrands I; Nielsen HM; Andersen P; Agger EM
Biochim Biophys Acta; 2007 Sep; 1768(9):2120-9. PubMed ID: 17555704
[TBL] [Abstract][Full Text] [Related]
9. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.
Henriksen-Lacey M; Bramwell VW; Christensen D; Agger EM; Andersen P; Perrie Y
J Control Release; 2010 Mar; 142(2):180-6. PubMed ID: 19874860
[TBL] [Abstract][Full Text] [Related]
10. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
[TBL] [Abstract][Full Text] [Related]
11. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
[TBL] [Abstract][Full Text] [Related]
12. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study.
Kastner E; Hussain MJ; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2015 Mar; 67(3):450-63. PubMed ID: 25677402
[TBL] [Abstract][Full Text] [Related]
13. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
Kaur R; Bramwell VW; Kirby DJ; Perrie Y
J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
[TBL] [Abstract][Full Text] [Related]
14. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
15. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.
Soleimanpour S; Farsiani H; Mosavat A; Ghazvini K; Eydgahi MR; Sankian M; Sadeghian H; Meshkat Z; Rezaee SA
Appl Microbiol Biotechnol; 2015 Dec; 99(24):10467-80. PubMed ID: 26373723
[TBL] [Abstract][Full Text] [Related]
16. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
[TBL] [Abstract][Full Text] [Related]
18. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
[TBL] [Abstract][Full Text] [Related]
19. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against
Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N
Front Immunol; 2018; 9():310. PubMed ID: 29535714
[TBL] [Abstract][Full Text] [Related]
20. Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA.
Kallerup RS; Franzyk H; Schiøth ML; Justesen S; Martin-Bertelsen B; Rose F; Madsen CM; Christensen D; Korsholm KS; Yaghmur A; Foged C
Mol Pharm; 2017 Jul; 14(7):2294-2306. PubMed ID: 28497975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
